Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

• Główni autorzy: Tessa Hosman (Autor), Roy van Heesbeen (Autor), Arangassery Rosemary Bastian (Autor), Weihong Hu (Autor), Christy Comeaux (Autor), Nynke Ligtenberg (Autor), Bart van Montfort (Autor), Benoît Callendret (Autor), Esther Heijnen (Autor)
• Format: Książka
• Wydane: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

ABSTRACTThis study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediate shelf-life (ISL) and near-presumed end-of-shelf-...